^
    No biomarker
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive: A1 - Approval
    No biomarker
    Waldenstrom Macroglobulinemia
    rituximab + ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    Waldenstrom Macroglobulinemia
    ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    Waldenstrom Macroglobulinemia
    acalabrutinib
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    fludarabine oral
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    cladribine
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    rituximab + bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    everolimus
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    ofatumumab
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    IRd
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    FCR
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    bortezomib + dexamethasone
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    bendamustine
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    BDR
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    BR
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    CaRD
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    RCD
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    RCP
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    venetoclax
    Sensitive: A2 - Guideline
    No biomarker
    Waldenstrom Macroglobulinemia
    CLR 131
    Sensitive: B - Late Trials
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive: B - Late Trials
    MYD88 wild-type
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive: B - Late Trials
    MYD88 mutation
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive: B - Late Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C2 – Inclusion Criteria
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C2 – Inclusion Criteria
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    venetoclax
    Sensitive: C2 – Inclusion Criteria
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    BDR
    Sensitive: C3 – Early Trials
    MYD88 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib
    Sensitive: C3 – Early Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib
    Sensitive: C3 – Early Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    rituximab
    Sensitive: C3 – Early Trials
    CXCR4 G336X
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 S338X
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 H350fs*
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 S338X + TP53 R196X
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 K327fs*
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 R338X
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 T318fs*
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 L326fs*
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    CXCR4 S347fs*
    Waldenstrom Macroglobulinemia
    rituximab + ixazomib
    Sensitive: C3 – Early Trials
    MYD88 L265P + CXCR4 mutation
    Waldenstrom Macroglobulinemia
    venetoclax
    Resistant: C3 – Early Trials
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    venetoclax
    Sensitive: C3 – Early Trials
    CD38 expression
    Waldenstrom Macroglobulinemia
    daratumumab
    Sensitive: C3 – Early Trials
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    daratumumab
    Sensitive: C3 – Early Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    daratumumab
    Sensitive: C3 – Early Trials
    MYD88 mutation + CXCR4 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib
    Sensitive: C3 – Early Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib + X4P-001
    Sensitive: C3 – Early Trials
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    X4P-001
    Sensitive: C3 – Early Trials
    CXCR4 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib + BMS-936564
    Sensitive: C3 – Early Trials
    MYD88 L265P
    Waldenstrom Macroglobulinemia
    orelabrutinib
    Sensitive: C3 – Early Trials
    MYD88 mutation + CXCR4 mutation
    Waldenstrom Macroglobulinemia
    ibrutinib + X4P-001
    Sensitive: C3 – Early Trials
    MYD88 mutation
    Waldenstrom Macroglobulinemia
    rituximab
    Sensitive: C4 – Case Studies